

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Kuramochi

RRID:CVCL_1345

Type: Cell Line

Proper Citation

RRID:CVCL_1345

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1345

Proper Citation: RRID:CVCL_1345

Description: Cell line Kuramochi is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:6268719](#), [PMID:7069245](#), [PMID:9290701](#), [PMID:11330945](#), [PMID:12417041](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:32612269](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Kuramochi

Synonyms: KURAMOCHI

Cross References: CLO:CLO_0037093, EFO:EFO_0006625, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:578, BioSample:SAMN03471055, BioSample:SAMN10988052, cancercellines:CVCL_1345, Cell_Model_Passport:SIDM00554, CGH-DB:9357-4, ChEMBL-Cells:ChEMBL3308307,

ChEMBL-Targets:CHEMBL2366119, Cosmic:809116, Cosmic:909975, Cosmic:931364, Cosmic-CLP:909975, DepMap:ACH-000524, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:909975, GEO:GSM186430, GEO:GSM186431, GEO:GSM659381, GEO:GSM888319, GEO:GSM1670012, IARC_TP53:1415, JCRB:JCRB0098, LiGeA:CCLE_899, LINCS_LDP:LCL-1701, PharmacDB:KURAMUCHI_796_2019, PRIDE:PXD003668, PRIDE:PXD030304, Progenetix:CVCL_1345, PubChem_Cell_line:CVCL_1345, Wikidata:Q54900722

ID: CVCL_1345

Record Creation Time: 20220427T220711+0000

Record Last Update: 20260905T180955+0000

Ratings and Alerts

No rating or validation information has been found for Kuramochi.

No alerts have been found for Kuramochi.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 52 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pradhan B, et al. (2026) Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. Cancer research, 86(4), 1073.

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. British journal of cancer, 134(12), 1830.

Saleh A, et al. (2026) CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3. Molecular oncology.

Uno K, et al. (2026) Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. Science advances, 12(6), eadu5944.

Sakaguchi-Mukaida H, et al. (2026) Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer. International journal of cancer, 159(1), 257.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Gros Lambert J, et al. (2026) PARG regulates the proteasomal degradation of TARG1. *Cell reports*, 45(1), 116789.

Bielesch S, et al. (2026) Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high-grade serous ovarian cancer. *Molecular oncology*.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Tan GYT, et al. (2026) BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC). *EMBO molecular medicine*, 18(5), 1933.

Resch V, et al. (2026) Targeting Steroid-Metabolizing Enzymes with 15 β -Substituted Estrone Analogues: Dual Discovery of AKR1C2/17 β -HSD1 Inhibitors and a Fluorescent 17 β -HSD1 Ligand. *Cancers*, 18(12).

Gudoityte G, et al. (2025) Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. *Molecular oncology*, 19(9), 2574.

Afenteva D, et al. (2025) Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer. *Cell reports. Medicine*, 6(9), 102316.

Ma J, et al. (2025) Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. *Molecular cancer therapeutics*, 24(8), 1171.

Musiani D, et al. (2025) Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. *Molecular cell*, 85(6), 1072.

Little S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. *iScience*, 28(6), 112555.

Glossner L, et al. (2025) Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer. *Molecular oncology*.

Tedeschi A, et al. (2025) Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. *Molecular cancer therapeutics*, 24(4), 550.

Dias MM, et al. (2025) SLC25A45 is required for mitochondrial uptake of methylated amino acids and de novo carnitine biosynthesis. *Molecular cell*, 85(21), 4093.

Bedia JS, et al. (2025) Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models. *Cell reports. Medicine*, 6(9), 102295.